The ADS ratio change is a mechanical price adjustment that does not fix the underlying business or cash runway. Monitor for a potential reverse-split-induced selloff as retail holders often exit after such events. The stock remains at high risk of delisting regardless of the ratio change, and the prior going-concern warning suggests limited time for a fundamental turnaround.
Price Chart
Executive Summary
Scinai Immunotherapeutics announced a 1-for-10 ADS ratio change effective August 21, 2026, to increase the per-ADS trading price and regain compliance with Nasdaq's $1.00 minimum bid price rule. This is a mechanical reverse-split equivalent with no change to the company's fundamentals, which remain distressed per the prior 20-F filing showing an $8.3M net loss, a $1.6M cash position, and a going-concern warning. The ADS ratio change is a routine compliance action that does not address the underlying business viability or Nasdaq delisting risk from continued low market cap.
Key Facts
- ADS ratio changes from 1 ADS : 4,000 ordinary shares to 1 ADS : 40,000 ordinary shares, effective August 21, 2026.
- The change has the same effect as a one-for-ten reverse split of the ADSs.
- The company is implementing the change to regain compliance with Nasdaq Listing Rule 5550(a)(2) requiring a minimum $1.00 bid price.
- The filing explicitly states 'there can be no assurance that the ADS Ratio Change will enable the Company to regain or maintain compliance.'
- Prior 20-F (April 2026) reported an $8.3M net loss, $1.6M cash, and substantial doubt about going concern.
Financial Impact
No new financial data in this filing. Prior 20-F reported $8.3M net loss and $1.6M cash position.
Risk Factors
- The ratio change may not achieve or maintain Nasdaq compliance.
- The company faces substantial doubt about its ability to continue as a going concern per the prior 20-F.
- A $1M market cap and $1.6M cash position leave minimal margin for error.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-091445 |
| Document: 0001213900-26-091445-index-headers.html | 0001213900-26-091445 |
| Document: 0001213900-26-091445-index.html | 0001213900-26-091445 |
| Document: 0001213900-26-091445.txt | 0001213900-26-091445 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $0.6813 | awaiting T+60 | — | $0.5301 (−22.19%) |
Oct 16, 2026 11d ago | 6-K | $0.7520 | awaiting T+60 | — | $0.5301 (+29.51%) |
Oct 16, 2026 11d ago | Press Release | $0.7524 | awaiting T+60 | — | $0.5301 (+29.55%) |
Oct 15, 2026 12d ago | 6-K | $0.9015 | awaiting T+60 | — | $0.5301 (+41.20%) |
Oct 13, 2026 14d ago | 6-K | $1.23 | awaiting T+60 | — | $0.5301 (−56.90%) |
Oct 6, 2026 21d ago | EFFECT | $1.22 | awaiting T+60 | — | $0.5301 (+56.55%) |
Sep 21, 2026 5w ago | 6-K | $1.69 | awaiting T+60 | — | $0.5301 (−68.63%) |
Aug 26, 2026 8w ago | 6-K | $2.87 | awaiting T+60 | — | $0.5301 (+81.53%) |
Aug 19, 2026 9w ago | 6-K | $0.2740 | awaiting T+60 | — | $0.5301 (−93.47%) |
Jun 17, 2026 18w ago | 6-K | $0.3370 $0.2440 | ▼ −27.60% | ▼ −30.28% | $0.5301 (+57.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers